{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Pirtobrutinib Shows Promise for Chronic Lymphocytic Leukemia

Activity Steps

1 Activity
2 Take Test 3Certificate

Learning Objectives

After completing this continuing education activity you will be able to:

  1. Identify biomarkers commonly found in patients with relapsed or refractory CLL or SLL.
  2. Synthesize the study results analyzing overall response, progression-free survival, and safety of pirtobrutinib in the treatment of CLL/SLL previously treated with a BTK inhibitor.

Learning Outcomes

Seventy-five percent of participants will demonstrate knowledge of a Phase I/II study that demonstrated the efficacy of pirtobrutinib as a treatment for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) patients who had previously received a covalent BTK inhibitor by achieving a minimum score of 70% on the outcomes-based posttest.

Disclosures

All authors, faculty, staff, and planners have no relevant financial relationships with any ineligible organizations regarding this educational activity.

Price: $12.95

Credits:

  • ANCC 1.0 CH
  • DC - BON 1.0 CH
  • FL - BON 1.0 CH
  • GA - BON 1.0 CH
  • NM - BON 1.0 CH
  • SC - BON 1.0 CH
  • WV - BOERN 1.0 CH

Lippincott Professional Development is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749. Lippincott Professional Development is also an approved provider of continuing nursing education by the District of Columbia Board of Nursing, Florida Board of Nursing, Georgia Board of Nursing, New Mexico Board of Nursing, South Carolina Board of Nursing, and West Virginia Board of Examiners for Registered Professional Nurses, #50-1223.













Planner
Test Code: OT0923
Published: September 2023
Expires: 9/5/2025
Sources: Oncology Times
Required Passing Score: 4/5 (80%)
Authors: Catlin Nalley
Categories: Advanced Practice Nursing , Cancer , Drug Therapy , Hematology , Oncology
Specialties: Advanced Practice Nursing, Oncology
Topics: Chronic Lymphocytic Leukemia (CLL)